Y-mAbs Therapeutics (YMAB) Competitors $4.35 +0.13 (+3.08%) Closing price 04:00 PM EasternExtended Trading$4.33 -0.02 (-0.55%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB vs. IMNM, SNDX, KALV, REPL, XERS, VIR, PHAR, GYRE, NUVB, and SANAShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Immunome (IMNM), Syndax Pharmaceuticals (SNDX), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Xeris Biopharma (XERS), Vir Biotechnology (VIR), Pharming Group (PHAR), Gyre Therapeutics (GYRE), Nuvation Bio (NUVB), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Y-mAbs Therapeutics vs. Its Competitors Immunome Syndax Pharmaceuticals KalVista Pharmaceuticals Replimune Group Xeris Biopharma Vir Biotechnology Pharming Group Gyre Therapeutics Nuvation Bio Sana Biotechnology Immunome (NASDAQ:IMNM) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Does the media refer more to IMNM or YMAB? In the previous week, Immunome had 4 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 5 mentions for Immunome and 1 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.87 beat Immunome's score of 1.41 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Immunome Positive Y-mAbs Therapeutics Very Positive Is IMNM or YMAB more profitable? Y-mAbs Therapeutics has a net margin of -31.84% compared to Immunome's net margin of -1,875.21%. Y-mAbs Therapeutics' return on equity of -30.59% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-1,875.21% -71.65% -60.36% Y-mAbs Therapeutics -31.84%-30.59%-22.70% Which has preferable valuation and earnings, IMNM or YMAB? Y-mAbs Therapeutics has higher revenue and earnings than Immunome. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$9.04M93.07-$292.96M-$3.18-3.04Y-mAbs Therapeutics$87.68M2.25-$29.67M-$0.64-6.80 Do analysts prefer IMNM or YMAB? Immunome currently has a consensus target price of $23.33, suggesting a potential upside of 141.30%. Y-mAbs Therapeutics has a consensus target price of $15.60, suggesting a potential upside of 258.62%. Given Y-mAbs Therapeutics' higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Y-mAbs Therapeutics 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.82 Which has more risk & volatility, IMNM or YMAB? Immunome has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Do institutionals & insiders hold more shares of IMNM or YMAB? 44.6% of Immunome shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryY-mAbs Therapeutics beats Immunome on 12 of the 17 factors compared between the two stocks. Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$191.10M$2.91B$5.52B$9.32BDividend YieldN/A2.46%3.76%4.05%P/E Ratio-6.807.7720.1819.43Price / Sales2.25300.75437.3299.95Price / CashN/A42.3835.5357.53Price / Book2.127.768.235.67Net Income-$29.67M-$55.11M$3.23B$257.51M7 Day Performance-2.03%0.95%-0.01%0.52%1 Month Performance-11.94%8.44%5.61%8.84%1 Year Performance-66.74%-2.38%26.52%14.18% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics4.1598 of 5 stars$4.35+3.1%$15.60+258.6%-67.5%$191.10M$87.68M-6.80150Positive NewsIMNMImmunome2.1471 of 5 stars$8.69-1.7%$23.33+168.5%-40.7%$756.12M$9.04M-2.7340News CoveragePositive NewsGap UpSNDXSyndax Pharmaceuticals3.0742 of 5 stars$8.73-3.0%$35.80+310.1%-62.2%$751.22M$23.68M-2.26110News CoverageAnalyst ForecastKALVKalVista Pharmaceuticals4.0395 of 5 stars$15.06+25.7%$24.14+60.3%+1.4%$748.78MN/A-4.05100Earnings ReportAnalyst RevisionHigh Trading VolumeREPLReplimune Group4.1221 of 5 stars$9.65+2.7%$20.83+115.9%+14.7%$743.92MN/A-3.14210News CoverageAnalyst ForecastOptions VolumeGap UpHigh Trading VolumeXERSXeris Biopharma3.9394 of 5 stars$4.70-1.1%$6.25+33.0%+113.3%$734.99M$203.07M-15.67290News CoverageVIRVir Biotechnology3.5707 of 5 stars$5.27-2.6%$32.86+523.5%-44.6%$728.51M$14.30M-1.25580PHARPharming Group2.079 of 5 stars$10.47-1.0%$30.00+186.5%+16.0%$719.77M$320.71M-52.35280Gap DownGYREGyre Therapeutics0.1257 of 5 stars$7.62-6.3%N/A-48.7%$714.45M$105.76M381.1940News CoverageNUVBNuvation Bio3.128 of 5 stars$2.08-0.5%$7.17+244.6%-37.9%$707.75M$10.96M-0.8960High Trading VolumeSANASana Biotechnology3.2386 of 5 stars$3.10-2.8%$9.17+195.7%-34.3%$698.98MN/A-3.52380 Related Companies and Tools Related Companies IMNM Competitors SNDX Competitors KALV Competitors REPL Competitors XERS Competitors VIR Competitors PHAR Competitors GYRE Competitors NUVB Competitors SANA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:YMAB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts